Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report - Top-Institutions - MDSpire

Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report

  • By

  • Ruiyue Wu

  • Xi Chen

  • Tong Li

  • Yunmei Zhang

  • Xiaoling Ling

  • May 4, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Breast Medical Oncology

  • #2

    Memorial Sloan Kettering Cancer Center (MSK)
    Memorial Sloan Kettering Cancer Center (MSK)

    New York, NY

    Key Differentiators

    • Oncology
    • Breast Oncology

  • #3

    Dana-Farber/Harvard Cancer Center
    Dana-Farber/Harvard Cancer Center

    Boston, MA

    Key Differentiators

    • Oncology
    • Breast Oncology

Original Source(s)

Efficacy analysis of disitamab vedotin (RC-48) in the treatment of HER2-low metastatic breast cancer: a case report

  • by Ruiyue Wu, Xi Chen, Tong Li, Yunmei Zhang, Xiaoling Ling

  • May 4, 2026

Related Content

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

Biotech exec Jeremy Levin on the industry’s strategic turning point

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation